Hermanns-Lê T, Scheen A, Piérard GE. - Acanthosis nigricans associated with insulin resistance : pathophysiology and management. Am J Clin Dermatol, 2004, 5, 199-203.
Slominski A, Wortsman J. - Neuroendocrinology of the skin. Endocr Rev, 2000, 21, 457-487.
Slominski A, Wortsman J, Kohn L, et al. - Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol, 2002, 119, 1449-1455.
Slominski A. - Neuroendocrine system of the skin. Dermatology, 2005, 21, 199-208.
Quatresooz P, Piérard-Franchimont C, Kharfi M, et al. - Skin in matury. The endocrine and neuroendocrine pathways. Int J Cosmet Sci, sous presse.
Esperanza LE, Fenske NA. - Hyperandrogenism, insulin resistance and acanthosis nigricans (AIR-AN) syndrome : spontaneous remission in a 15-year-old girl. J Am Acad Dermatol, 1996, 34, 892-897.
Moller DE, Flier JS. - Insulin resistance - mechanisms, syndromes and implications. N Engl J Med, 1991, 325, 938-948.
Jaffiol C, Rouard M, Mcari F, et al. - Résistance à l'insuline : du diagnostic clinique à la génétique moléculaire. Bull Acad Natl Med, 1999, 183, 1761-1775.
Kuroki R, Sadamoto Y, Imamura M, et al. - Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism. Improvement by diet control. Dermatology, 1999, 198, 164-166.
Ramirez-Amador V, Esquivel-Pedraza L, Callabero-Mendoza E. - Oral manifestations as a hallmark of malignant acanthosis nigricans. J Oral Pathol Med, 1999, 28, 278-281.
Cruz PDJr, Hud JA Jr. - Excess insulin binding to insulin-like growth factor receptors : proposed mechanism for acanthosis nigricans. J Invest. Dermatol, 1992, 98, 82S-85S.
Humbert P, Nguyen N. - Physiopathologie de l'acanthosis nigricans. Ann Dermatol Venereol, 1998, 125, 851-855.
Rique S, Nogues C, Ibanez L, et al. - Identification of three novel mutations in the insulin receptor gene in type A insulin resistant patients. Clin Genet, 2000, 57, 67-69.
Ellis DL, Kafka SP, Chow JC, et al. - Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trelat, and multiple acrochordons. N Engl J Med, 1987, 317, 1582-1587.
Wilgenbus K, Lentner A, Kuckelkorn R, et al. - Further evidence that acanthosis nigricans maligna is linked to enhanced secretion by the tumor by transforming growth factor alpha. Arch Dermatol Res, 1992, 284, 266-270.
Koyama S, Ikeda K, Sato M, et al. - Transforming growth factor-alpha (TGF-alpha)-producing gastric carcinoma with acanthosis nigricans : an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol, 1997, 32, 71-77.
Baird JS, Johnson JL, Elliott-Mills JS, et al. - Systemic lupus erythematosus, acanthosis nigricans, hyperpigmentation and insulin receptor antibody. Lupus, 1997, 6, 275-278.
Magsino CH, Spencer J. - Insulin receptor antibodies and insulin receptor. South Med J, 1999, 92, 717-719.
Taylor SI, Arioglu E. - Syndromes associated with insulin resistance and acanthosis nigricans. J Basic Clin Physiol Pharmacol, 1998, 9, 419-439.
Akovbyan VA, Talanin NY, Arifov SS, et al. - Successful treatment of acanthosis nigricans with etretinate. J Am Acad Dermatol 1994, 31, 118-120.
Bohm M, Luger TA, Metze D. - Treatment of mixed type acanthosis nigricans with topical calcipotriol. Br J Dermatol, 1998, 139, 932-934.
